Letter to the Editor - Clinical trials during COVID-19: Keeping clinical trial participants informed during this pandemic

July 30, 2020

Louis X. Wong, MS, in collaboration with physician-in-training Bryant Chee, MS from Touro University College of Osteopathic Medicine – California and Jasmine M. Park from Rush University Medical College, published a Letter to the Editor "Clinical trials during COVID-19: Keeping clinical trial participants informed during this pandemic" in the Journal of Clinical Research and Trials.

The manuscript urges investigators, institutions, ethics review boards and Sponsors to disclose beyond the traditional elements of the risks, benefits, and alternatives to a clinical intervention, such as possible delays in investigational treatments or suspension of clinical trial activities due to COVID-19. As with any clinical trial and especially during this pandemic, it is key to maintain deep trust and open communications between the investigator and participant.

In addition to cross-functional and multi-disciplinary collaborations, we thank the healthcare professionals all around the world combating against COVID-19. Together, we can make a difference to maintain patient safety and improve health outcomes. Additionally, we thank the following individual for their academic support and guidance in clinical research and the informed consent process: Samar Nasser, PhD MS MPH (The George Washington University) and Andrew H. Ko, MD (University of California, San Francisco).

To view the full publication please visit https://www.oatext.com/